Targeting the prostate-specific membrane antigen for prostate cancer therapy
| Autor: | Philipp Wolf, Ursula Elsässer-Beile, Patrick Bühler |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Glutamate Carboxypeptidase II
Male Oncology medicine.medical_specialty medicine.medical_treatment Immunology Lymphocyte Activation Prostate cancer Antigen Antigens Neoplasm Prostate Internal medicine Antibodies Bispecific medicine Glutamate carboxypeptidase II Animals Humans Immunology and Allergy business.industry Prostatectomy Gene Expression Profiling Carcinoma Prostatic Neoplasms Epithelial Cells Immunotherapy medicine.disease Radiation therapy medicine.anatomical_structure Radioimmunodetection Antigens Surface Hormonal therapy business T-Lymphocytes Cytotoxic |
| Zdroj: | Immunotherapy. 1:471-481 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt.09.17 |
| Popis: | Prostate cancer remains a leading cause of death for men in Western civilization. Despite the effectiveness of surgical prostatectomy, radiotherapy and hormonal therapy, a significant proportion of patients progress to advanced metastatic disease for which there are currently no curative treatment options. Therefore, new therapeutic approaches need to be considered. The prostate-specific membrane antigen is a cell-surface glycoprotein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer at all stages. These characteristics make it an attractive target for antibody-based imaging and therapies and the first anti-prostate-specific membrane antigen agents have already entered clinical trials. The proposed strategies include targeted toxins and radiotherapeutics as well as immunotherapeutic agents and vaccines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|